Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and Durable Responses to CARVYKTI ™ (ciltacabtagene autoleucel) in Heavily Pretreated Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 4, 2022 – – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the Phase 1b/2 CARTITUDE-1 study evaluating the efficacy and safety of CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy. The study included patients with relapsed or refractory multiple myeloma (RRMM) who had received >3 lines of therapy including a proteasome inhibitor (PI), an anti-CD38 monoclonal antibody and an immunomodulatory agent (IMiD) or were double refractory to an IMiD and PI a...
Source: Johnson and Johnson - June 4, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Phase 3 SHINE Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
This study is one of the largest clinical trials ever conducted in first-line MCL and the first for a Bruton’s tyrosine kinase inhibitor (BTKi).[1] The data are being presented in an oral session and featured in a press briefing during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, and were published in The New England Journal of Medicine today. The data will also be presented as an oral presentation at the 2022 European Hematology Association (EHA) Annual Congress. MCL is a type of aggressive, rare non-Hodgkin lymphoma (NHL) that is incurable and difficult to treat.[2] It commonly affects people o...
Source: Johnson and Johnson - June 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
European Commission Grants Conditional Approval of CARVYKTI ® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
BEERSE, BELGIUM, 26 May 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disease progression on the last therapy. In December 2017, Janssen Biotech, Inc. (Janssen) entered into an exclusive worldwide license a...
Source: Johnson and Johnson - May 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
Gabapentin May Cut Opioid Needs for Oral Mucositis Pain During RT
MONDAY, May 23, 2022 -- For patients receiving concurrent chemoradiotherapy for squamous cell carcinoma of the head and neck, higher doses of gabapentin are well tolerated and associated with delayed time to first opioid use for additional pain... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 23, 2022 Category: Pharmaceuticals Source Type: news
Mouth cancer symptoms: Are you experiencing ear pain? Check with your GP
AROUND 8,300 people are diagnosed with mouth cancer each year in the UK, which is about one in every 50 cancers diagnosed, according to the NHS. There are several signs which may occur, and ear pain may indicate you should speak to your GP. (Source: Daily Express - Health)
Source: Daily Express - Health - May 19, 2022 Category: Consumer Health News Source Type: news
New Data Show TREMFYA ® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
SPRING HOUSE, PENNSYLVANIA, May 18, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the first results of the in vitro MODIF-Y studies, supporting a hypothesis that may differentiate the mechanism of first-in-class TREMFYA® (guselkumab) from risankizumab due to the ability of TREMFYA to bind to CD64 positive (CD64+) cells in addition to interleukin (IL)-23 — both of which are key components of the immune system. 1,2 These findings, which are being presented at the Society for Investigative Dermatology (SID) annual meeting May 18-21, 2022 in Portland, Oregon, demonstrate TREMFYA bind...
Source: Johnson and Johnson - May 18, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
F.D.A. Authorizes Underwear to Protect Against S.T.I.s During Oral Sex
It ’s the first time underwear has been authorized for this purpose, and it provides a new choice for protection where the few options have been unpopular. (Source: NYT Health)
Source: NYT Health - May 12, 2022 Category: Consumer Health News Authors: Pam Belluck Tags: Sex Head and Neck Cancer Lingerie and Underwear Sexually Transmitted Diseases Women and Girls Mouth Vagina Human Papillomavirus (HPV) Food and Drug Administration your-feed-science your-feed-healthcare Source Type: news
Oral Retinoid May Ease Painful Skin Reactions to Anticancer Therapy
(MedPage Today) -- Acitretin (Soriatane) may improve outcomes for cancer patients with multikinase inhibitor (MKI)-mediated hand-foot skin reaction (HFSR), according to a small retrospective study.
Of eight MKI users who developed HFSR, seven... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - May 12, 2022 Category: Dermatology Source Type: news
Gordon MacRae: Oklahoma! star's alcoholism could have caused mouth cancer before death
STAR of Oklahoma! Gordon MacRae sadly passed away aged 64. Usually playing the leading man next to Doris Day, MacRae had success in nearly every industry whether it be on the stage, screen or on the radio. Behind the scenes the star also had his fair share of health battles, including alcoholism and cancer, a short while before his death from pneumonia in 1986. (Source: Daily Express - Health)
Source: Daily Express - Health - May 7, 2022 Category: Consumer Health News Source Type: news
Oral health: How to spot the signs of mouth cancer at home – ‘it could save your life’
MOUTH cancer is defined as cancer that forms on the inside of the mouth. Depending on where in the mouth the cancer is will depend on what type of mouth cancer it is. Just like all forms of cancer, it is crucial to diagnose the condition as soon as possible; this means keeping an eye out for any changes at home. (Source: Daily Express - Health)
Source: Daily Express - Health - May 3, 2022 Category: Consumer Health News Source Type: news
Mayo Clinic Q & amp;A podcast: Advances in oral cancer treatment, reconstruction
Oral cancer refers to cancers that originate in the mouth, tongue and back of the throat. Treatment options, which can vary based on the cancer's location and stage, include surgery, radiation and chemotherapy. The use of anatomic modeling and 3D printing have led to advances in surgical treatments for oral cancer. "One of the advances that we've seen in the last 20 or 30 years in the treatment of head and neck cancers certainly has… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - April 26, 2022 Category: Databases & Libraries Source Type: news
Cancer: Bleeding in the mouth is a warning sign – and other symptoms
CANCER is one of the most common diseases in the UK. Cancer can develop anywhere in the body, including in the mouth. As with other cancers, it is crucial to be aware of the symptoms so action can be taken. (Source: Daily Express - Health)
Source: Daily Express - Health - April 19, 2022 Category: Consumer Health News Source Type: news
Johnson & Johnson Reports Q1 2022 Results
New Brunswick, N.J. (April 19, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2022. “Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-based commitment to delivering transformative healthcare solutions to patients and customers around the world,” said Joaquin Duato, Chief Executive Officer. “Looking ahead, I remain confident in the future of Johnson & Johnson as we continue advancing our portfolio and inno...
Source: Johnson and Johnson - April 19, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
